BioSpace News Archive

Willow Biosciences Inc. is pleased to announce that the Board of Directors has appointed Dr. Chris Savile, Willow’s Chief Operations Officer, as President and Chief Executive Officer and Mr. Trevor Peters, a Director and Founder of the Company, as Chairman, effective March 28, 2023, in connection with Dr. Peter Seufer-Wasserthal’s retirement as President and CEO.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced its financial results for the fourth quarter ended December 31, 2022, and provided corporate updates.

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) announced that it will be exhibiting at the CPHI North America Conference in Philadelphia, Pennsylvania April 25-27, 2023.

Grey Wolf Therapeutics today announced dosing of the first patient in the initial monotherapy module of an adaptive Phase 1/2 clinical trial evaluating GRWD5769, the company’s investigational first-in-class ERAP1 inhibitor.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences.

Sirnaomics Ltd. has announced its audited annual results for the year ended 31 December 2022 (the “Year”).

Aruna Bio, Inc. announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been named one of the first recipients of Entrepreneur Distinction from The University System of Georgia Board of Regents.

Immuneering Corporation, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced that it has appointed Harold E. Brakewood as its Chief Business Officer.

Vaccitech plc (NASDAQ: VACC) today announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis B (HBV) infection.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.